Compare TransMedics Group Inc (TMDX) vs Zillow Group Inc Class A (ZG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Zillow Group Inc Class A — how do they compare? TransMedics Group Inc trades at $78.15 (market cap $2.74B), while Zillow Group Inc Class A trades at $29.8 (market cap $6.59B). The key difference: Zillow Group Inc Class A is far larger — about 2.4× TransMedics Group Inc's market cap, and TransMedics Group Inc is trading nearer its 52-week high, Zillow Group Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Zillow Group Inc Class A for 86 Days on average.
| TMDX | ZG | |
|---|---|---|
Market Cap | $2.74B | $6.59B |
Volume | 949,331 | 1,361,381 |
Sector | Health | Media |
52-Week High | $150.42 | $74.58 |
52-Week Low | $61.99 | $27.70 |
Typical Hold Time | 24 Days | 86 Days |
Enterprise Value | $3.13B | $6.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Zillow Group (ZG) trades at $29.53, up 5.58% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. Fundamentally, the company reported a return to profitability in 2025 with net income of $23 million, and revenue is projected to grow to $2.8 billion in 2026. Recent news highlights the company's focus on AI integration and a challenging housing market environment.
The outlook is cautiously optimistic, with a consensus price target of $48.87 suggesting significant upside. Key opportunities include revenue growth and market share gains, while risks involve housing market volatility and intense competition. Analyst sentiment is mixed, with a near-even split between Buy and Hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Zillow Group Inc Class A
Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →
